Sec Form 4 Filing - Papadopoulos Romilos @ Viveon Health Acquisition Corp. - 2020-12-23

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Papadopoulos Romilos 2. Issuer Name and Ticker or Trading Symbol Viveon Health Acquisition Corp. [ VHAQ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) CFO and Treasurer (Last) (First) (Middle) 3953 HOLCOMB BRIDGE ROAD, SUITE 200 3. Date of Earliest Transaction (MM/DD/YY) 12/23/2020 (Street) NORCROSS, GA30092 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $0.0001 per share 12/23/2020 J 81,000 ( 1 ) D $ 0 4,950,250 I Viveon Health LLC ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants to purchase common stock $ 11.5 ( 3 ) 12/28/2020 P 18,000,000 ( 3 ) ( 4 ) ( 4 ) Common Stock, par value $0.0001 9,000,000 $ 0.5 18,000,000 I Viveon Health LLC ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Papadopoulos Romilos 3953 HOLCOMB BRIDGE ROAD, SUITE 200 NORCROSS, GA30092 X X CFO and Treasurer Signatures /s/ Rom Papadopoulos 01/04/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Reflects the transfer of 81,000 founders shares, in the aggregate, to the independent directors of the Issuer for their service on the board of directors. There was no consideration paid in the transfer. ( 2 )Mr. Papadopoulos is the managing member of Viveon Health LLC. The business address for Viveon Health LLC is c/o Gibson, Deal & Fletcher, PC, Spalding Exchange, 3953 Holcomb Bridge Road, Suite 200, Norcross Georgia 30092. ( 3 )Viveon Health LLC, purchased from the Issuer an aggregate of 18,000,000 private warrants, at $0.50 per private warrant, with each warrant exercisable for one- half of a share of common stock at an exercise price of $11.50 per whole share. The purchase was on a private placement basis simultaneously with the consummation of this offering. ( 4 )The warrants will become exercisable on the later of (i) one year after the closing the Issuer's initial public offering (12/28/21), or (ii) the consummation of the Issuer's initial business combination. The warrants will expire at 5:00 p.m., New York City time, on the fifth anniversary of the Issuer's completion of an initial business combination, or earlier upon redemption.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.